BAKER BROS. ADVISORS LP sold $317.8M of CELC (indirect holdings)

BAKER BROS. ADVISORS LP sold 3,100,000 indirectly-held shares of Celcuity Inc. (CELC) at $102.50 ($317.75M total) across 2 trades on 2026-07-14.

Original reporting
SEC EDGAR · BAKER BROS. ADVISORS LP
Published Jul 16, 2026, 9:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 9:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CELC
Neutral
medium confidence
Mentioned
$CELC
Relevance
9/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CELCNeutralLow
01

Why it matters

A reported open-market sale of 3.1M shares at $102.50 totals about $317.75M, which can influence short-term sentiment but does not, by itself, change company fundamentals.

02

Market read

Traders may monitor CELC for follow-on selling signals, but the text provides no new operational catalyst or guidance change.

03

What to watch

No 10b5-1 plan is stated, but the filing does not provide intent, cost basis, or whether other related entities increased/decreased holdings around the same time.

Relevance 9/10Novelty 5/10Timing: after-hours/filing update on 2026-07-16 for a 2026-07-14 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Celcuity Inc. (CELC) reported by Baker Bros. Advisors LP as an indirect holding.

Company-level read

Ticker impact

$CELCNeutralMedium confidence
Context

Celcuity (CELC) disclosed a $317.75M indirect open-market sale by Baker Bros. Advisors on 3.1M shares at $102.50.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any impact is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider transaction disclosure with no 10b5-1 plan and no accompanying company-specific operational or guidance change in the text.

Market effects

Limited sector read-through because the disclosure is company-specific and does not cite industry/regulatory developments.

None indicated; this is a US-listed issuer Form 4.

None indicated.

Counterpoint

The sale is indirect and may reflect portfolio rebalancing or tax/liquidity needs rather than a bearish view on Celcuity’s fundamentals.

Key entities

  • Celcuity Inc.

    Subject of the Form 4 disclosure; shares sold indirectly by Baker Bros. Advisors LP.

  • Baker Bros. Advisors LP

    Reported the indirect open-market sale of 3,100,000 CELC shares.

  • SEC Form 4

    Primary-source disclosure of insider transaction details, filed 2026-07-16.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CELCHighAI 8/10

FDA accepts Celcuity application for expanded breast cancer use

Celcuity Inc. (CELC) announced the FDA accepted its application to expand the use of REVTORPYK for treating specific breast cancer patients. The FDA set a review goal date of June 25, 2027, based on Phase 3 trial data. The drug is already approved for a similar indication without PIK3CA mutations. Celcuity is developing REVTORPYK for other cancer treatments.

$CELCHighAI 8/10

Celcuity (CELC) Q3 2026 Earnings Call Transcript

Celcuity (CELC) reported strong Q3 2026 results, with Revtopik, its drug for advanced breast cancer, showing high adoption. 78% of top accounts ordered it, and 91% of U.S. commercial and Medicare lives have coverage. The company estimates a $9B annual market. Clinical data showed significant efficacy, and Celcuity plans to submit data to global regulators.

$CELCMedAI 8/10

What Celcuity (CELC) Said on Its Q3 Earnings Call

Celcuity (CELC) reported Q3 earnings, highlighting sufficient production capacity and regulatory updates. The company submitted a supplemental new drug application to the FDA and expects to provide further data to global regulators. Operating expenses rose to $77.3M, driven by commercial spending. Celcuity ended the quarter with $642.7M in cash and expects it to fund operations through 2029.

$CELCLow

Celcuity 3Q 2026: Revenue $0, EPS ($1.33) — 10-Q Summary

Celcuity reported no revenue in Q3 2026, with a net loss of $73.34M and EPS of ($1.33). Expenses rose due to commercialization efforts. REVTORPYK launched commercially, and the company submitted an sNDA for its use in advanced breast cancer. New data was presented at ESMO Congress, and a prostate cancer study showed promising results.